# Exicure, Inc.: overview XCUR · Nasdaq · CIK 1698530 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/xcur.md) · [Financials](/companies/xcur/financials.md) · [Filings](/companies/xcur/filings.md) · [Insiders](/companies/xcur/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-352011.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-352011). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001698530-25-000100.md) | [0.0 d](/filings/0001698530-26-000028.md) | [0.0](/filings/0001698530-26-000057.md) | [0.0](/filings/0001193125-26-352011.md) | [0.0](/filings/0001698530-25-000100.md) | [0.0 d](/filings/0001698530-26-000028.md) | [0.0](/filings/0001698530-26-000057.md) | [0.0](/filings/0001193125-26-352011.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.57)](/filings/0001698530-25-000100.md) | not reported | [0.49](/filings/0001698530-26-000057.md) | [(0.41)](/filings/0001193125-26-352011.md) | [(0.39)](/filings/0001698530-25-000100.md) | not reported | [(0.29)](/filings/0001698530-26-000057.md) | [(0.18)](/filings/0001193125-26-352011.md) | | Free cash flow | $k | [(449) d](/filings/0001698530-25-000100.md) | [(845) d](/filings/0001698530-26-000028.md) | not reported | not reported | [(3,634) d](/filings/0001698530-25-000100.md) | [(1,360) d](/filings/0001698530-26-000028.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [(0.5)](/filings/0001698530-23-000029.md) | [28.8](/filings/0001698530-24-000051.md) | [0.0](/filings/0001698530-25-000019.md) | [0.5](/filings/0001698530-26-000028.md) | [0.0](/filings/0001698530-26-000028.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [12950.1%](/filings/0001698530-23-000029.md) | [(6.4%)](/filings/0001698530-24-000051.md) | not reported | [(2446.4%)](/filings/0001698530-26-000028.md) | not reported | | Net margin | % | [13271.6%](/filings/0001698530-23-000029.md) | [(9.0%)](/filings/0001698530-24-000051.md) | not reported | [(1940.2%)](/filings/0001698530-26-000028.md) | not reported | | Diluted EPS | $ per share | [(21.70)](/filings/0001698530-23-000029.md) | [(0.56)](/filings/0001698530-24-000051.md) | [(10.55)](/filings/0001698530-25-000019.md) | [(4.75)](/filings/0001698530-26-000028.md) | [(0.79)](/filings/0001698530-26-000028.md) | | Free cash flow | $m | [(35.8)](/filings/0001698530-23-000029.md) | [(35.7)](/filings/0001698530-24-000051.md) | [(10.4)](/filings/0001698530-25-000019.md) | [(2.9)](/filings/0001698530-26-000028.md) | [(8.6)](/filings/0001698530-26-000028.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xcur/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $89.7k | 43,111 | | Added +10,128 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $65.0k | 31,249 | | Reduced −5,664 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $61.4k | 29,535 | | New +29,535 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $31.0k | 14,919 | | New +14,919 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $27.4k | 13,161 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $8.5k | 4,074 | | Added +3,585 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $711 | 342 | | Reduced −524 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $297 | 143 | | Reduced −15 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $89 | 43 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $73 | 35 | | Reduced −9,318 | ## Recent filings [All 528 filings](/companies/xcur/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-16 | 06:27 ET | [8-K](/filings/0001193125-26-392654.md) | 3.01 Delisting notice | 0001193125-26-392654 | | 2026-08-14 | 15:27 ET | [10-Q](/filings/0001193125-26-352011.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352011 | | 2026-07-17 | 13:05 ET | [SCHEDULE 13D/A](/filings/0002046701-26-000008.md) | Ownership report, active investor, amended | 0002046701-26-000008 | | 2026-06-30 | 14:55 ET | [8-K](/filings/0001193125-26-290264.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-290264 | | 2026-06-01 | 15:30 ET | [8-K](/filings/0001698530-26-000060.md) | 7.01 Regulation FD disclosure | 0001698530-26-000060 | | 2026-05-29 | 14:09 ET | [10-Q](/filings/0001698530-26-000057.md) | Quarterly report, period 2026-03-31 | 0001698530-26-000057 | | 2026-04-10 | 16:15 ET | [8-K](/filings/0001698530-26-000036.md) | 5.02 Departure or appointment of officers or directors | 0001698530-26-000036 | | 2026-04-02 | 16:15 ET | [8-K](/filings/0001698530-26-000034.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001698530-26-000034 | | 2026-03-27 | 16:40 ET | [8-K](/filings/0001698530-26-000031.md) | 5.02 Departure or appointment of officers or directors | 0001698530-26-000031 | | 2026-03-25 | 16:42 ET | [10-K](/filings/0001698530-26-000028.md) | Annual report, period 2025-12-31 | 0001698530-26-000028 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001698530-26-000028.md), filed Mar 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5afa2b96-2571-415c-a3d8-820c0eb2ed8a) ## About the filer - CIK: 1698530 - Tickers: XCUR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.